Gimeracil
Dihydropyrimidine dehydrogenase inhibitor / Gimeracil is a dihydropyrimidine dehydrogenase (DPD) inhibitor. DPD is involved in the degradation of pyrimidine-based chemotherapeutic drugs such as 5-fluorouracil (5-FU). Gimeracil is used along with 5-FU or Tegafur to prolong circulating concentrations of the drugs.1,2 Gimeracil has also been shown to act as a radiosensitizer via inhibition of homologous recombination in the repair of DNA double strand breaks.3
Biochemicals & reagents
103766-25-2
1) Diasio (1999) Clinical implications of dihydropyrimidine dehydrogenase inhibition; Oncology(Williston Park). 13 17 2) Kobayakawa and Kojima (2011), Tegafur/giimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies; Onco.Targets Ther. 4 193 3) Sakata et al. (2011), Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination; Cancer Sci. 102 1712
-20°C
TARGET: Dehydrogenase (GAPDH, GPDH, IMPDH, PHGDH, LDH, DHODH, ALDH, GDH, IDH, UGDH, DPD, DHPDH, KGDH, PDH, and MDH); DNA -- PATHWAY: DNA damage -- DISEASE AREA: Cancer